Gross Profit Comparison: Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc. Trends

Pharmaceutical Giants' Gross Profit Trends: 2014-2023

__timestampAmphastar Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014512560001256834000000
Thursday, January 1, 2015773470001271973000000
Friday, January 1, 20161041890001173296000000
Sunday, January 1, 2017907950001274610000000
Monday, January 1, 20181069850001437534000000
Tuesday, January 1, 20191319230002201424000000
Wednesday, January 1, 20201433400002203504000000
Friday, January 1, 20211997390002462160000000
Saturday, January 1, 20222488600002783406000000
Sunday, January 1, 20233511210002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Infusing magic into the data realm

Gross Profit Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Takeda, a global leader, consistently outperformed with a staggering 1,000% higher gross profit than Amphastar in 2023. However, Amphastar's growth is noteworthy, with a 585% increase over the decade, reflecting its strategic market positioning. Takeda's profits peaked in 2023, showing a 125% rise since 2014, despite a plateau in 2024. This data highlights the dynamic nature of the pharmaceutical sector, where both established giants and emerging players can thrive. Missing data for 2024 suggests potential volatility, urging stakeholders to stay informed. Dive into these insights to grasp the financial pulse of these industry titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025